Pharma Reputations in 2012

January 2013. An independent study, called “The corporate reputation of Pharma – the patient perspective” and funded by PatientView, represents 600 patient groups’ latest impressions on the corporate reputation of 29 individual pharma companies and of the pharma industry as a whole.

The overall reputation of pharma declined in 2012. Only 34% of the patient groups responding to the survey state that multinational pharma companies had an “Excellent” or “Good” reputation during 2012. The equivalent figure from the 500 patient groups responding to the 2011 survey was 42%. 40% of the respondent patient groups state that the reputation of the pharma industry had declined during 2012.

For the purposes of this report, the phrase ‘corporate reputation’ is defined as the extent to which pharma companies are meeting the expectations of patients and patient groups.
Janssen was number 4 out of 29 in the ranking of pharmaceutical companies with the best reputation with patients.

PatientView is a UK based research, publishing and consultancy group.